Characteristics of Real-World Patients with High-Risk BRAFV600E/K-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through th... by Quaglino P, Ascierto PA, Consoli F, Queirolo P, Spagnolo F, Morelli MF, Berardi R, Chiarion-Sileni V, Tucci M, Troiani T, Melotti B, Rossi E, Mandala M, Rinaldi G, Marcon IG, Pizzuti M, Del Vecchio M

Get full text

Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial by Weber, J, Del Vecchio, M, Mandala, M, Gogas, H, Arance, A, Dalle, S, Cowey, C, Schenker, M, Grob, J, Chiarion-Sileni, V, Marquez-Rodas, I, Butler, M, Maio, M, Middleton, M, Tang, T, Saci, A, De Pril, V, Lobo, M, Larkin, J, Ascierto, P